Ionis registers Phase 3 trial of obudanersen for Angelman syndrome due to UPD or imprinting defects

This week brought one new registry entry for Ionis Pharmaceuticals.

• Ionis registered "CHAMPION," a Phase 3, open-label, single-arm study of obudanersen (ION582) in participants with Angelman syndrome caused by paternal uniparental disomy or imprinting defects. The trial is a multi-center study focused on this specific genetic subtype of Angelman syndrome.¹ The study is not yet recruiting, plans to enroll 30 participants¹, and its primary outcome is change from baseline in performance on the expressive communication domain of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1, measured at Week 52¹.